TENS for Chemotherapy-Induced Neuropathy in Breast Cancer
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, since the trial involves patients actively undergoing chemotherapy, it seems likely that you can continue your current treatment.
Is TENS safe for use in humans?
How does the TENS treatment differ from other treatments for chemotherapy-induced neuropathy?
TENS (Transcutaneous Electrical Nerve Stimulation) is unique because it uses mild electrical currents to stimulate nerves through electrodes placed on the skin, which can be self-administered at home. Unlike other treatments that may involve medications, TENS offers a non-drug approach to managing pain and symptoms associated with chemotherapy-induced neuropathy.14567
What is the purpose of this trial?
This phase II trial examines transcutaneous electrical nerve stimulation (TENS) in patients with stage I-III breast cancer with chemotherapy induced peripheral neuropathy. TENS is a procedure in which mild electric currents are applied to some areas of the skin to potentially improve neuropathy. This trial may help determine if TENS is feasible and effective for the treatment of peripheral neuropathy symptoms while on chemotherapy.
Research Team
Manali A Bhave, MD
Principal Investigator
Emory University Hospital/Winship Cancer Institute
Eligibility Criteria
This trial is for women with stage I-III breast cancer experiencing nerve pain due to chemotherapy. They must be undergoing treatment with paclitaxel or docetaxel, not pregnant, able to follow the study plan, and use birth control if of childbearing age. Excluded are those with skin issues where TENS pads go, epilepsy, electronic implants like pacemakers, existing neuropathy or prior neurotoxic chemo.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo TENS therapy at home daily over 1 hour for 14 days
Follow-up
Participants are monitored for changes in symptoms and functional impairment, with assessments at 2 and 6 weeks
Treatment Details
Interventions
- Transcutaneous Electrical Nerve Stimulation
Transcutaneous Electrical Nerve Stimulation is already approved in United States, European Union, Canada for the following indications:
- Pain management
- Musculoskeletal pain
- Neck pain
- Back pain
- Knee osteoarthritis pain
- Overactive bladder
- Urinary retention
- Temporomandibular joint dysfunction
- Essential tremor
- Pain management
- Musculoskeletal pain
- Neck pain
- Back pain
- Knee osteoarthritis pain
- Overactive bladder
- Urinary retention
- Temporomandibular joint dysfunction
- Essential tremor
- Pain management
- Musculoskeletal pain
- Neck pain
- Back pain
- Knee osteoarthritis pain
- Overactive bladder
- Urinary retention
- Temporomandibular joint dysfunction
- Essential tremor
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor
National Cancer Institute (NCI)
Collaborator